VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced its decision to voluntarily discontinue clinical development of ZW171, a T cell engager designed to target gynecological, thoracic, and digestive system cancers. ZW171 i ...

Core Viewpoint - Zymeworks Inc. is set to report its second quarter 2025 financial results on August 7, 2025, and will participate in several investor conferences during July and August, highlighting its commitment to advancing its biotherapeutics pipeline for difficult-to-treat diseases [1][2]. Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving care for conditions such as cancer, inflammation, and autoimmune diseases [2]. - The company has developed zanidatamab, a HER2-targeted bispecific antibody, which has received accelerated approval from the U.S. FDA and conditional approvals from China's NMPA and the European Commission for treating adults with unresectable or metastatic HER2-positive biliary tract cancer [2]. - Zanidatamab is the first dual HER2-targeted bispecific antibody approved for this indication in the U.S., Europe, and China, and is being evaluated in global clinical trials for multiple HER2-expressing cancers [2]. Upcoming Events - Zymeworks will host a conference call and webcast on August 7, 2025, at 4:30 pm ET to discuss its financial results and provide a corporate update [1]. - The company will participate in the BTIG Virtual Biotechnology Conference on July 29, 2025, and the Stifel Biotech Summer Summit from August 11-13, 2025, including a fireside chat on August 13 at 9:00 am ET [3]. Pipeline Development - Zymeworks is advancing a robust pipeline of wholly-owned product candidates, with Phase 1 studies for ZW171 and ZW191 actively recruiting, and an investigational new drug application for ZW251 planned for mid-2025 [2]. - The company leverages its therapeutic platforms through strategic partnerships with global biopharmaceutical companies to enhance its drug development capabilities [2].